Medicaid volume pressures, underperforming facilities and drag on performance, capital expenditure strategy are the key contradictions discussed in Acadia Healthcare's latest 2025Q2 earnings call.
Revenue and Patient Volume Growth:
-
reported
total revenue of
$869.2 million for Q2 2025, up
9.2% over the same period last year.
- While
same-facility patient days increased by
1.8%, this was slightly below expectations due to underperforming facilities and weaker Medicaid volumes in the acute care business.
- The growth was driven by strong performance in specialty and CTC lines of business.
Quality and Patient Safety Initiatives:
- Acadia emphasized the importance of quality patient care, highlighting investments in technology and safety measures.
- The company implemented remote patient monitoring devices and wearable safety devices for staff, enhancing patient safety and care consistency.
- These efforts are part of an ongoing strategy to improve clinical outcomes and meet payers' focus on value-based care.
Financial Performance and Outlook:
- Adjusted
EBITDA for Q2 was
$201.8 million, reflecting a
7.5% increase over the same period last year.
- Acadia updated its full-year 2025 adjusted EBITDA guidance to
$675 million to $700 million due to lower expected volume growth and higher start-up costs.
- These adjustments were partially offset by higher anticipated supplemental payments, including a
$40 million to $45 million recurring benefit from the Tennessee program.
Regulatory and Legislative Impact:
- Acadia discussed the potential impact of the One Big Beautiful Bill Act, noting that reduced supplemental payments from existing state Medicaid programs may commence in fiscal 2028.
- The company does not expect significant impacts from Medicaid work requirements as exemptions apply to many of their patient populations.
- Acadia remains committed to expanding access to behavioral health services and integrating mental health into broader healthcare systems.
Comments
No comments yet